Sr. Territory Account Manager (Mountain West)
Illumina- Full Time
- Senior (5 to 8 years)
GRAIL is a healthcare company pioneering new technologies for early cancer detection. Our mission is to detect cancer early, when it can be cured, by transforming cancer care through innovative, safe, and effective technologies. We have assembled a multi-disciplinary organization of scientists, engineers, and physicians, leveraging next-generation sequencing (NGS), population-scale clinical studies, and advanced computer and data science. Headquartered in Menlo Park, California, GRAIL also has locations in Washington, D.C., North Carolina, and the United Kingdom, supported by leading global investors and industry partners.
This opportunity is within GRAIL's growing commercial team, where you will serve as a GRAIL Galleri Consultant (GGC). You will work closely with sales leadership and internal stakeholders to execute the go-to-market sales strategy for GRAIL’s revolutionary multi-cancer early detection (MCED) product, Galleri.
This is a customer-focused role requiring a "market builder" mindset. A successful GGC will act with urgency and passion to engage physicians and their staff, encouraging them to adopt MCED technology into their workflow and offer it to appropriate patients for earlier cancer detection. GRAIL is the first company globally to introduce MCED technology to patients and clinicians, presenting a unique career opportunity.
GRAIL is dedicated to detecting cancer early, when it can be cured. We are committed to changing the trajectory of cancer mortality by uniting stakeholders to adopt innovative, safe, and effective technologies that can transform cancer care. GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom. The company is backed by leading global investors and prominent pharmaceutical, technology, and healthcare companies. More information can be found at grail.com.
Develops blood tests for early cancer detection
GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages, enhancing treatment success rates. The company utilizes high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning to extract actionable information for early cancer detection. GRAIL differentiates itself from competitors by its commitment to large-scale clinical studies that validate the effectiveness of its tests. The primary goal is to reduce global cancer mortality by enabling early diagnosis, making the disease more treatable.